CBD News

Using CBD to Treat Schizophrenia
GW Pharmaceuticals – a UK based biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform – recently announced that it has started Phase 2 clinical trials on a potential drug for the treatment of schizophrenia made from the marijuana compound cannabidiol (CBD). The...

How Might Cannabidiol Impact Schizophrenia?
Cannabidiol (CBD) is a compound that has shown possible benefits in studies on a variety of animal models of mental health, including anxiety, bipolar disorder, and obsessive-compulsive disorder. Researchers have likewise also begun to examine CBD's potential utility with schizophrenia. Recently, we discussed a CBD clinical trial for schizophrenic individuals...

CBD and Schizophrenia
According to the National Institute of Mental Health, schizophrenia is “a chronic and severe mental disorder that affects how a person thinks, feels, and behaves” that may cause a person to dissociate from reality with sometimes debilitating symptoms. Medical News Today explains that symptoms can include auditory or visual hallucinations,...

Get Involved: CBD Clinical Trials
Updated 3/17/2018 - Link added to include international studies, which expands the number of trials from 53 to 140! Research into the effects of cannabinoids, including cannabidiol, continues to progress into exploring an astonishing variety of systems and disorders. Although government restrictions on cannabis research hindered advancement until very recently, currently research...